The adjustment in price target by Wedbush reflects a nuanced view on Pharvaris's future performance. While the Outperform rating indicates a positive outlook, the reduction in price target suggests a tempering of expectations. This could lead to mixed reactions in the short term, as investors weigh the positive rating against the lowered price expectations.